AVTX - Avalo Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $316.1. This is a potential upside of $307.2 (3451.69%) from yesterday's end of day stock price of $8.9.

Avalo Therapeutics's activity chart (see below) currently has 3 price targets and 10 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 22.22% with an average time for these price targets to be met of 3.33 days.

Most recent stock forecast was given by LELAND GERSHELL from OPPENHEIMER on 27-Jun-2023. First documented stock forecast 18-Nov-2020.

Best performing analysts who are covering AVTX - Avalo Therapeutics:

Chris Howerton Leland Gershell Gregory Renza

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$2400

2 years 1 months 23 days ago
(27-Jun-2023)

0/1 (0%)

$909.6 (61.03%)

Hold

$180

$170.98 (1895.57%)

2 years 1 months 24 days ago
(26-Jun-2023)

0/2 (0%)

$60 (50.00%)

Hold

$720

$711.82 (8701.96%)

$2160

2 years 6 months 11 days ago
(08-Feb-2023)

2/3 (66.67%)

$-48 (-6.25%)

10

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is AVTX (Avalo Therapeutics) average time for price targets to be met?

On average it took 3.33 days on average for the stock forecasts to be realized with a an average price target met ratio 22.22

Which analyst has the current highest performing score on AVTX (Avalo Therapeutics) with a proven track record?

CHRIS HOWERTON

Which analyst has the current lower performing score on AVTX (Avalo Therapeutics) with a proven track record?

GREGORY RENZA

Which analyst has the most public recommendations on AVTX (Avalo Therapeutics)?

Chris Howerton has 8 price targets and 3 ratings on AVTX

Which analyst is the currently most bullish on AVTX (Avalo Therapeutics)?

Chris Howerton with highest potential upside - $711.82

Which analyst is the currently most reserved on AVTX (Avalo Therapeutics)?

Leland Gershell with lowest potential downside - -$0

Avalo Therapeutics in the News

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX),...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?